Ionis Pharmaceuticals, Inc. IONS
44.50
0.69
1.57%
as of 25 Sep
- Market cap
- $7.4B
- P/E
- 0.0×
Follow IONS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.81 | 13.41 | 11.70 | 15.01 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(79.52) | (91.92) | (15.62) | 23.19 | |
P/B ratio |
16.91 | 25.88 | 25.19 | 29.83 | |
Price to Tangible BV |
17.76 | 27.55 | 26.81 | 31.98 | |
EV/Sales |
9.15 | 12.46 | 11.57 | 14.69 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(35.84) | (43.79) | (13.44) | (25.87) | |
EV/FCF |
(28.60) | (36.11) | (12.52) | (22.63) | |
Quick Ratio |
2.51 | 3.51 | 2.78 | 6.70 | |
Current Ratio |
2.79 | 3.83 | 4.10 | 7.89 | |
Net Debt/EBITDA |
10.33 | 4.26 | 5.01 | 7.31 | |
Debt/Assets |
19.65% | 50.50% | 39.11% | 45.12% | |
Debt/Equity |
0.96 | 3.64 | 2.75 | 3.07 | |
Asset Turnover |
0.32 | 0.29 | 0.34 | 0.29 | |
Operating CF/Net income |
1.02 | 0.60 | 8.57 | (4.93) | |
Capex/Depreciation |
(6.48) | (6.23) | (6.45) | (2.99) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
138.95% | 137.53% | 85.40% | 81.03% | |
Selling, General and Administrative Expense of Revenue |
61.77% | 64.03% | 61.10% | 56.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
19.87% | 21.31% | 17.58% | 17.02% | |
Graham Net Nets |
0.01 | 0.00 | 0.00 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.46%) | (2.98%) | (2.65%) | (4.36%) | |
Free Cash Flow Yield |
(2.96%) | (2.57%) | (7.90%) | (4.33%) | |
Revenue per Share |
0.98 | 1.27 | 1.49 | 1.62 | |
Operating CF per Share |
(0.82) | (0.86) | (4.81) | 3.42 | |
Capex per Share |
(0.04) | (0.14) | (0.14) | (0.11) | |
Free Cash Flow per Share |
(0.87) | (1.00) | (4.95) | 3.31 | |
Cash per Share |
14.02 | 16.73 | 11.64 | 12.42 | |
Shareholders Equity per Share |
3.87 | 3.06 | 2.98 | 2.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.87 | 3.06 | 2.98 | 2.66 | |
Free Cash Flow |
(138.37) | (160.37) | (816.07) | 547.30 | |
Working Capital |
1,615.54 | 2,209.07 | 2,220.35 | 2,175.64 | |
Capital Expenditures |
(6.93) | (22.66) | (23.25) | (18.23) | |
Net Current Asset Value |
103.87 | (44.11) | (21.61) | (63.49) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.11 | 0.09 | 0.07 | |
Net Profit Margin |
(82.06%) | (112.82%) | (37.60%) | (42.79%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
21.27 | 79.12 | 56.70 | 55.71 | |
Average Payables |
11.69 | 35.52 | 21.74 | 35.25 | |
Average Inventory |
19.46 | 11.28 | 8.53 | 29.66 | |
Average Assets |
3,057.10 | 3,263.76 | 3,131.46 | 2,989.82 | |
Average Common Equity |
640.22 | 538.72 | 483.57 | 535.73 |
Columns are period end dates